US FDA consults on lowering risk classification level of implanted blood access devices
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is inviting stakeholder feedback on its proposal to lower the risk classification level of implanted blood access devices, from Class III to Class II with special controls.